Skip to content


SELECTRA INVESTMENTS SICAV – J. LAMARCK PHARMA sub-fund aims at benefiting from increasing share prices in the pharmaceutical sector worldwide. The focus is on mature top tier pharmaceutical companies and companies with interesting pipeline of products in development in a single or numerous markets. The followed investment policy will enable the sub-fund to increase overall return by active stock selection of companies, offering the most promising technology platform. 

To achieve this investment objective, the sub-fund will take long positions in these shares issued mainly by worldwide issuers. In order to lower overall risk the sub-fund will not invest in derivatives (such as single stock futures, index futures, warrants or options) to meet the sub-fund’s investment objective. The sub-fund may use financial derivative instruments for the purpose of hedging currency risks only. 

The sub-fund may invest up to 10% of its total net assets in shares/units of UCITS and/or other UCIs (including ETF).

Expand your business efficiently across borders

Get in touch to find out how we can help your organisation grow in a complex world.

Contact us Contact us